Arterial Disease Multifactorial Intervention Trial (ADMIT)

• Status: Completed
• Trial end date: 1999-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Beta Carotene; Carotenoids; Pravastatin; Vitamin E; Vitamins; Warfarin

Criteria

Men and women with symptomatic or asymptomatic peripheral arterial disease.